About this Research Topic
The combination of immune checkpoint inhibitors (ICIs) with chemotherapy has revolutionized cancer immunotherapy, significantly improving patient outcomes across various malignancies. ICIs, by blocking proteins that inhibit T-cell activation, restore immune system function to target and eliminate tumor cells. However, resistance to ICIs remains a significant challenge, along with the potential for severe immune-related side effects. Chemotherapy, traditionally used to kill rapidly dividing cells, can enhance the efficacy of ICIs by modulating the tumor microenvironment, reducing immune suppression, and promoting immunogenic cell death. Recent advances in nanomedicine, small-molecule inhibitors, and biologics offer new opportunities to optimize these combination therapies. This research topic aims to provide an in-depth examination of the mechanisms, efficacy, and challenges associated with combining ICIs and chemotherapy, emphasizing innovative strategies to overcome resistance and minimize toxicity.
The primary goal of this Research Topic is to advance the understanding and application of combined immune checkpoint inhibitors (ICIs) with chemotherapy in cancer immunotherapy. This special issue seeks to address key challenges such as drug resistance and immune evasion mechanisms, while exploring strategies to reduce adverse effects commonly associated with these treatments. By encouraging innovative approaches, the topic aims to uncover new synergistic effects between ICIs and chemotherapy, including the role of nanomedicines, small-molecule drugs, and biologics. Additionally, it strives to promote translational research that bridges preclinical findings with clinical applications, ultimately improving therapeutic outcomes for cancer patients.
This research topic welcomes original research, reviews, and clinical trials in the following areas:
• Mechanisms of drug resistance in ICI and chemotherapy combinations
• Strategies to reduce toxicity and side effects in combination therapies
• The role of nanomedicine in enhancing ICI and chemotherapy efficacy
• Small-molecule drugs and their impact on tumor immune evasion
• Biologics in combination with ICIs and chemotherapy
• Preclinical and clinical results on novel drug delivery systems
• Advances in overcoming immune suppression in the tumor microenvironment
• Case studies and real-world applications of combination therapies
The primary goal of this Research Topic is to advance the understanding and application of combined immune checkpoint inhibitors (ICIs) with chemotherapy in cancer immunotherapy. This special issue seeks to address key challenges such as drug resistance and immune evasion mechanisms, while exploring strategies to reduce adverse effects commonly associated with these treatments. By encouraging innovative approaches, the topic aims to uncover new synergistic effects between ICIs and chemotherapy, including the role of nanomedicines, small-molecule drugs, and biologics. Additionally, it strives to promote translational research that bridges preclinical findings with clinical applications, ultimately improving therapeutic outcomes for cancer patients.
This research topic welcomes original research, reviews, and clinical trials in the following areas:
• Mechanisms of drug resistance in ICI and chemotherapy combinations
• Strategies to reduce toxicity and side effects in combination therapies
• The role of nanomedicine in enhancing ICI and chemotherapy efficacy
• Small-molecule drugs and their impact on tumor immune evasion
• Biologics in combination with ICIs and chemotherapy
• Preclinical and clinical results on novel drug delivery systems
• Advances in overcoming immune suppression in the tumor microenvironment
• Case studies and real-world applications of combination therapies
Keywords: immune checkpoint inhibitors, chemotherapy, cancer immunotherapy, drug resistance, tumor microenvironment
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
